Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
Shixue Chen(Chinese PLA General Hospital), Yi Hu(Union Hospital), Zhefeng Liu(Chinese People's Liberation Army), Zhaozhen Wu(Nankai University), Haitao Tao(Chinese People's Liberation Army), Sujie Zhang(Chinese People's Liberation Army), Zhibo Zhang(Nanjing Drum Tower Hospital), Jinliang Wang(Tianjin University), Ziwei Huang(Stomatology Hospital), Pengfei Cui(Chinese PLA General Hospital), Yuanyu Qian(Chinese People's Liberation Army), Xuan Zheng(Jinan University), Junxun Ma(Chinese People's Liberation Army), Di Huang(South China Agricultural University)
Cited by 125
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer
|Cell Research|2017|225
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias
|Molecular Cancer Therapeutics|2006|186
Structural and Functional Characterization of Human CXCR4 as a Chemokine Receptor and HIV-1 Co-receptor by Mutagenesis and Molecular Modeling Studies
|Journal of Biological Chemistry|2001|138
Bio-template synthesis of Mo-doped polymer carbon nitride for photocatalytic hydrogen evolution
|Applied Catalysis B: Environmental|2019|133